Zydus Gets USFDA Approval for Sitagliptin Tablets

Deepthi | Myequity news | Date : 11-09-2018 11:50:00 IST

Zydus Cadila has received the tentative approval from the USFDA for Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg (US RLD - Januvia® Tablets). It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Sitagliptin is in a class of medications called dipeptidyl peptidase - 4 (DPP-4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high.

About Zydus Cadila:

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.


More from Myequity